Table 1.
Demographics and baseline characteristics of patients with coronavirus disease 2019 and odds ratio of death
| Died | Recovered | Odds ratio | p value | |
|---|---|---|---|---|
| Total | 21 | 13 | ||
| Sex | ||||
| Male | 10 | 9 | 0.415 (0.070–2.102) | 0.296 |
| Female | 11 | 4 | ||
| Age | ||||
| ≥ 70 | 16 | 11 | 0.591 (0.048–4.471) | 0.682 |
| < 70 | 5 | 2 | ||
| ≥ 80 | 6 | 3 | 1.322 (0.216–10.099) | 1 |
| < 80 | 15 | 10 | ||
| Disease | ||||
| Cancer | 19 | 12 | 0.797 (0.012–16.907) | 1 |
| Not cancer | 2 | 1 | ||
| Treated with steroids in past 1 month | ||||
| Yes | 12 | 4 | 2.901 (0.573–17.369) | 0.172 |
| No | 9 | 9 | ||
| Lymphocytes, (μl) | ||||
| < 1000 | 17 | 8 | 2.576 (0.425–17.009) | 0.254 |
| ≥ 1000 | 4 | 5 | ||
| White blood cell count (μl) | ||||
| < 4000 | 8 | 6 | 0.725 (0.143–3.668) | 0.728 |
| ≥ 4000 | 13 | 7 | ||
| Lactate dehydrogenase, units per l | ||||
| ≥ 250 | 7 | 3 | 1.642 (0.281–12.286) | 0.704 |
| < 250 | 14 | 10 | ||
| Treated with favipiravir | ||||
| Yes | 13 | 7 | 1.379 (0.273–6.990) | 0.728 |
| No | 8 | 6 | ||
| Treated with nafamostat mesylate | ||||
| Yes | 14 | 6 | 2.273 (0.455–12.105) | 0.296 |
| No | 7 | 7 | ||
| Treated with ciclesonide | ||||
| Yes | 8 | 6 | 0.725 (0.143–3.668) | 0.728 |
| No | 13 | 7 | ||
| Remission | ||||
| No | 17 | 5 | 10.758 (1.459–138.874) | 0.0118 |
| Yes | 2 | 7 | ||
| Origin of tumor | ||||
| Lymphoid | 14 | 5 | 3.734 (0.667–23.879) | 0.13 |
| Myeloid | 5 | 7 | ||
| Chemotherapy | ||||
| With prednisolone | 12 | 3 | 8.350 (1.111–88.068) | 0.0344 |
| Without prednisolone | 3 | 7 | ||
| Hypertension | ||||
| Yes | 10 | 3 | 2.933 (0.535–21.415) | 0.2763 |
| No | 11 | 10 | ||
| Diabetes | ||||
| Yes | 7 | 4 | 1.121 (0.206–6.814) | 1 |
| No | 14 | 9 | ||